Ozempic is becoming cheaper for Medicare beneficiaries: Falling prices are welcome news for seniors’ wallets. But a new proposal to expand access to GLP-1s for Medicare members could threaten the federal health insurance program itself.
Lawmakers criticize HHS plan to regulate healthcare AI: Their position stands in stark contrast to physicians, who could refuse to use the tech if it’s not properly vetted.
Declining revenue, data breaches, and user mistrust jeopardize its future, leaving its vast genetic data trove in limbo as the company struggles to pivot.
US hospitals increase use of robots for surgical procedures: But healthcare marketers must do a better job educating the public on how robotic-assisted surgery works as more folks shop around for the best surgical care.
Social health influencers can change physicians’ prescribing choices: But only if a campaign focuses on certain factors physicians value, like credibility.
Trump’s healthcare picks will look to rein in GLP-1 spending: His selections to run the FDA and HHS aren’t big proponents of widespread GLP-1 use for weight loss. We explore what it could mean for the obesity drug market amid a new administration.
Most US patients want their PCP to ask about mental health: Yet fewer report that this happens. Lack o With a lack of affordable access to mental health treatment in the US, primary care providers could play a key role in identifying behavioral issues earlier.
Headspace transitions therapist network to contract and part-time roles: Telemental health companies are placing less of an emphasis on therapists and more on AI.
CMS must recalculate UnitedHealthcare’s Medicare Advantage star ratings: The ruling could be a good omen for Medicare Advantage insurers whose ratings were downgraded.
CMS must recalculate UnitedHealthcare’s Medicare Advantage star ratings: The ruling could be a good omen for Medicare Advantage insurers whose ratings were downgraded.
Consumers are willing to try at-home blood tests: We explore why companies in this market may still struggle to reel in customers despite their desire for convenience.
Pharmacy closures, medication shortages threaten access to meds: We examine some digital tools that drugmakers and pharmacies should endorse to ensure patients stay on their prescriptions.
Big 3 pharmacy benefit managers countersue FTC: They allege the FTC's case against them over insulin prices is unconstitutional. While it might be a savvy legal tactic, it shouldn’t divert attention from PBMs’ role in rising prescription drug costs.
Consumers are submitting medical scans to Elon Musk’s genAI chatbot, Grok: But Grok isn’t trained well enough on medical data, which could create a host of problems for patients.
Nearly one-quarter of working-age US adults are underinsured: More consumers are being pushed onto less generous health plans, which will inevitably result in sicker patients with higher amounts of medical debt.
Trump taps Dr. Oz to helm the CMS: We detail what the celebrity doctor’s appointment would mean for the future of Medicare, Medicaid, the Affordable Care Act, and consumers enrolled in these plans.
Over 80% of ad spending in the US for technology and electronics (87.1%), retail (82.9%), and consumer packaged goods (80.2%) is directed toward digital media, according to Ä¢¹½AV’s August 2024 forecast.
On today’s podcast episode, we discuss why mega-pharmacies are struggling, why 7-Eleven is closing and opening a lot of stores, and what the new model of convenience will look like. Tune in to the discussion with Senior Director of Podcasts and host Marcus Johnson and Senior Analysts Blake Droesch and Rajiv Leventhal.
The vertical’s spending on digital advertising will surge 12.5% this year, driven by a 14.2% spike in pharma, per our estimates.
On today's podcast episode, we discuss how physicians are thinking about AI, the specific problems in healthcare that AI is trying to solve, and what it should never be used for in the space. Tune in to the discussion with host Marcus Johnson and analyst Rajiv Leventhal.